<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine&#187; Pharmacy</title>
	<atom:link href="http://www.rxtimes.com/category/pharmacynews/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 09 Jan 2012 03:45:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program</title>
		<link>http://www.rxtimes.com/pfizer-wins-corporate-citizenship-award-for-global-health-partnerships-program/</link>
		<comments>http://www.rxtimes.com/pfizer-wins-corporate-citizenship-award-for-global-health-partnerships-program/#comments</comments>
		<pubDate>Sat, 19 Nov 2011 05:00:45 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Corporate Citizenship Award]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5567</guid>
		<description><![CDATA[Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “Pfizer is proud to [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/pfizer-wins-corporate-citizenship-award-for-global-health-partnerships-program/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis and collaborators discover new dual-acting class of antimalarial compounds with potential to both prevent and treat malaria infections</title>
		<link>http://www.rxtimes.com/novartis-and-collaborators-discover-new-dual-acting-class-of-antimalarial-compounds-with-potential-to-both-prevent-and-treat-malaria-infections/</link>
		<comments>http://www.rxtimes.com/novartis-and-collaborators-discover-new-dual-acting-class-of-antimalarial-compounds-with-potential-to-both-prevent-and-treat-malaria-infections/#comments</comments>
		<pubDate>Fri, 18 Nov 2011 04:49:31 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[antimalarial compounds]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[Novartis]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5563</guid>
		<description><![CDATA[The discovery of a new class of dual-acting antimalarial compounds &#8211; the imidazolopiperazines (IZPs) &#8211; was published in the journal Science online, at the Science Express website today[1]. The findings report on compounds that target both liver and blood infections, attacking the Plasmodium parasite at both stages in its reproduction cycle. The findings describe how [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/novartis-and-collaborators-discover-new-dual-acting-class-of-antimalarial-compounds-with-potential-to-both-prevent-and-treat-malaria-infections/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Foundation Awards $2.34 Million in Grants to Help Prisoners with Mental Illness Return to Community</title>
		<link>http://www.rxtimes.com/foundation-awards-2-34-million-in-grants-to-help-prisoners-with-mental-illness-return-to-community/</link>
		<comments>http://www.rxtimes.com/foundation-awards-2-34-million-in-grants-to-help-prisoners-with-mental-illness-return-to-community/#comments</comments>
		<pubDate>Fri, 18 Nov 2011 04:47:25 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5561</guid>
		<description><![CDATA[The numbers are sobering: more than two million arrests in the United States each year involve people with serious mental illnesses (SMI). By the best and most recent estimate, nearly one in three women and one in seven men in our nation’s jails suffer from depression, bipolar disorder, schizophrenia or other mental illnesses. “These individuals [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/foundation-awards-2-34-million-in-grants-to-help-prisoners-with-mental-illness-return-to-community/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)</title>
		<link>http://www.rxtimes.com/first-therapy-approved-in-the-european-union-for-the-rare-and-fatal-neurodegenerative-disease-transthyretin-familial-amyloid-polyneuropathy-ttr-fap/</link>
		<comments>http://www.rxtimes.com/first-therapy-approved-in-the-european-union-for-the-rare-and-fatal-neurodegenerative-disease-transthyretin-familial-amyloid-polyneuropathy-ttr-fap/#comments</comments>
		<pubDate>Fri, 18 Nov 2011 04:43:42 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[tafamidis]]></category>
		<category><![CDATA[Transthyretin Familial Amyloid Polyneuropathy]]></category>
		<category><![CDATA[TTR-FAP]]></category>
		<category><![CDATA[Vyndaqel®]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5559</guid>
		<description><![CDATA[Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “Today marks a real breakthrough for patients in the EU living [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/first-therapy-approved-in-the-european-union-for-the-rare-and-fatal-neurodegenerative-disease-transthyretin-familial-amyloid-polyneuropathy-ttr-fap/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes</title>
		<link>http://www.rxtimes.com/meta-analysis-of-clinical-data-on-cardiovascular-safety-presented-for-investigational-compound-dapagliflozin-in-adult-patients-with-type-2-diabetes/</link>
		<comments>http://www.rxtimes.com/meta-analysis-of-clinical-data-on-cardiovascular-safety-presented-for-investigational-compound-dapagliflozin-in-adult-patients-with-type-2-diabetes/#comments</comments>
		<pubDate>Thu, 17 Nov 2011 04:40:33 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[Dapagliflozin]]></category>
		<category><![CDATA[Type 2 Diabetes]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5557</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a pre-specified meta-analysis of cardiovascular (CV) safety data from 14 Phase 2b/3 trials in adult patients with type 2 diabetes, which showed that the investigational compound dapagliflozin was not associated with an unacceptable increase in CV risk relative to all comparators pooled [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/meta-analysis-of-clinical-data-on-cardiovascular-safety-presented-for-investigational-compound-dapagliflozin-in-adult-patients-with-type-2-diabetes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011</title>
		<link>http://www.rxtimes.com/abbott-statement-on-the-results-of-the-aim-high-study-presented-at-aha-2011/</link>
		<comments>http://www.rxtimes.com/abbott-statement-on-the-results-of-the-aim-high-study-presented-at-aha-2011/#comments</comments>
		<pubDate>Wed, 16 Nov 2011 04:34:52 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[AHA]]></category>
		<category><![CDATA[AHA 2011]]></category>
		<category><![CDATA[AIM-HIGH study]]></category>
		<category><![CDATA[American Heart Association]]></category>
		<category><![CDATA[Niaspan]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5553</guid>
		<description><![CDATA[Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test whether raising HDL &#8220;good&#8221; cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL &#8220;bad&#8221; cholesterol [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/abbott-statement-on-the-results-of-the-aim-high-study-presented-at-aha-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kathryn Joosten Speaks Out About Lung Cancer Profiles</title>
		<link>http://www.rxtimes.com/kathryn-joosten-speaks-out-about-lung-cancer-profiles/</link>
		<comments>http://www.rxtimes.com/kathryn-joosten-speaks-out-about-lung-cancer-profiles/#comments</comments>
		<pubDate>Tue, 15 Nov 2011 04:29:11 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Life+People]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Kathryn Joosten]]></category>
		<category><![CDATA[Lung Cancer]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5551</guid>
		<description><![CDATA[Kathryn Joosten, two-time Emmy® Award-winning actress and star of Desperate Housewives and The West Wing, is opening up about her 10-year battle with lung cancer as part of a new national campaign, Lung Cancer Profiles. Lung Cancer Profiles aims to reduce the stigma associated with lung cancer by educating about the diversity of the disease [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/kathryn-joosten-speaks-out-about-lung-cancer-profiles/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>F.A.C.E. Diabetes and Anthony Anderson Ask Americans to Rethink Generation D</title>
		<link>http://www.rxtimes.com/f-a-c-e-diabetes-and-anthony-anderson-ask-americans-to-rethink-generation-d/</link>
		<comments>http://www.rxtimes.com/f-a-c-e-diabetes-and-anthony-anderson-ask-americans-to-rethink-generation-d/#comments</comments>
		<pubDate>Fri, 11 Nov 2011 17:04:41 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Life+People]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Anthony Anderson]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[F.A.C.E.]]></category>
		<category><![CDATA[Type 2 Diabetes]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5549</guid>
		<description><![CDATA[For the second year in a row, award-winning actor and comedian Anthony Anderson is teaming up with Eli Lilly and Company&#8217;s Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative to remove the stereotype of Generation D—the belief that type 2 diabetes is an older person&#8217;s disease. Formerly known as &#8220;adult-onset&#8221; diabetes, type 2 diabetes is [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/f-a-c-e-diabetes-and-anthony-anderson-ask-americans-to-rethink-generation-d/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lilly to Recognize Employees Who Have Served Our Country Through the Military</title>
		<link>http://www.rxtimes.com/lilly-to-recognize-employees-who-have-served-our-country-through-the-military/</link>
		<comments>http://www.rxtimes.com/lilly-to-recognize-employees-who-have-served-our-country-through-the-military/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 13:15:14 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Life+People]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[Veterans Day]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5532</guid>
		<description><![CDATA[U.S. military veterans employed by Eli Lilly and Company (NYSE: LLY) will be recognized for their service to the country during a special Veterans Recognition Event at the Lilly Corporate Center 4 p.m. Monday, Nov. 14. The event is sponsored by the Veterans Leadership Network (VLN), an employee resource group at Lilly, and by Employer [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/lilly-to-recognize-employees-who-have-served-our-country-through-the-military/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals</title>
		<link>http://www.rxtimes.com/novartis-appoints-timothy-wright-m-d-as-global-head-development-novartis-pharmaceuticals/</link>
		<comments>http://www.rxtimes.com/novartis-appoints-timothy-wright-m-d-as-global-head-development-novartis-pharmaceuticals/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 13:13:31 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Business+Technology]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[M.D.]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Timothy Wright]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5530</guid>
		<description><![CDATA[Novartis announced the appointment of Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals effective immediately. Dr Wright joined Novartis in 2004 and most recently served as Senior Vice President and Global Head of Translational Sciences at Novartis Institutes for BioMedical Research (NIBR). His group included Translational Medicine, Biomarker Development, Preclinical Safety (toxicology), and Drug [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/novartis-appoints-timothy-wright-m-d-as-global-head-development-novartis-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

